Q4 2019 13F Holders as of 31 Dec 2019
-
Type / Class
-
Equity / COM
-
Number of holders
-
57
-
Total 13F shares, excl. options
-
15.1M
-
Shares change
-
-600K
-
Total reported value, excl. options
-
$167M
-
Value change
-
-$137K
-
Number of buys
-
35
-
Number of sells
-
-21
-
Price
-
$11.06
Significant Holders of Kiniksa Pharmaceuticals Intern - COM (KNSA) as of Q4 2019
67 filings reported holding KNSA - Kiniksa Pharmaceuticals Intern - COM as of Q4 2019.
Kiniksa Pharmaceuticals Intern - COM (KNSA) has 57 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 15.1M shares
.
Largest 10 shareholders include BAKER BROS. ADVISORS LP (2.8M shares), ArrowMark Colorado Holdings LLC (2.28M shares), HILLHOUSE CAPITAL ADVISORS, LTD. (1.9M shares), VANGUARD GROUP INC (1.2M shares), AMERIPRISE FINANCIAL INC (1.15M shares), BlackRock Inc. (948K shares), Sofinnova Investments, Inc. (923K shares), Hudson Bay Capital Management LP (440K shares), Alyeska Investment Group, L.P. (387K shares), and CITADEL ADVISORS LLC (366K shares).
This table shows the top 57 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.